The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.

Authors

Trevor R. Baybutt, Thomas Jefferson UniversityFollow
Allison A. Aka, Thoams Jefferson UniversityFollow
Adam E. Snook, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

9-15-2017

Comments

This article has been peer reviewed. It is the author’s final published version in Toxins

Volume 9, Issue 9, September 2017, Article number 282.

The published version is available at DOI: 10.3390/toxins9090282. Copyright © Baybutt et al.

Abstract

Cancer immunotherapy is becoming a routine treatment modality in the oncology clinic, in spite of the fact that it is a relatively nascent field. The challenge in developing effective immunotherapeutics is the identification of target molecules that promote anti-tumor efficacy across the patient population while sparing healthy tissue from damaging autoimmunity. The intestinally restricted receptor guanylyl cyclase C (GUCY2C) is a target that has been investigated for the treatment of colorectal cancer and numerous animal, and clinical studies have demonstrated both efficacy and safety. Here, we describe the current state of GUCY2C-directed cancer immunotherapy and the future directions of this work.

Recommended Citation

Baybutt, Trevor R.; Aka, Allison A.; and Snook, Adam E., "The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report." (2017). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 88.
https://jdc.jefferson.edu/petfp/88

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

28914772